A very recent study showed that higher pre-treatment levels of CD133+/CD34+/CD45dim cells (called circulating progenitor cells in that study) were associated with the worst outcome of suntinib therapy in hepatocellular carcinoma (Zhu et al, 2009). This evidence concerns the gene PROM1 and hepatocellular carcinoma.